Re: [Renaliste] Hypercalcémie

[Dr Alfredo ZANNIER]

Je viens de faire une recherche biblio et n'ai pas trouvé mention d'interférence. D'après le résumé infra il n'y en aurait pas.

Alfredo Zannier, MD, MSc
(Sent from my iPhone)

On 16 nov. 2011, at 18:38, Patrick GIRAUD <pkgiraud at wanadoo.fr> wrote:

> Message de la liste nephrologique francophone RENALISTE
> ----------------------------------
> Le 16/11/11 18:04, « EMOND christian » <christian.emond at ch-carcassonne.fr> a
> écrit :
> 
>> le MIMPARA ne pertuberait-il pas la scintigraphie ?
> 
> Question très intéressante, pour laquelle toutes les expériences seront
> bienvenues...

Dual-phase 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism
Fuster, David; Torregrosa, José-Vicente; Domenech, Beatriz; Solà, Oriol; Martín, Gloria; Casellas, Joan; Setoain, Xavier; Muxí, Africa; Pons, Francesca

Nuclear Medicine Communications . 30(11):890-894, November 2009.
doi: 10.1097/MNM.0b013e3283305df6

Abstract

Objective: To evaluate the effect of calcimimetics with 99mTc-methoxy-isobutyl-isonitrile (MIBI) parathyroid scintigraphy in secondary hyperparathyroidism.

Methods: This prospective study included 30 consecutive haemodialysis patients with inadequately controlled secondary hyperparathyroidism despite standard medical treatment. Patients were given a single daily oral dose of 30 mg of cinacalcet. A baseline and 1-year follow-up dual-phase99mTc-MIBI scintigraphy were performed.99mTc-MIBI uptake in each parathyroid gland was graded on a semiquantitative scale (scoring 0-3).

Results: Twenty-one of the 30 patients responded to cinacalcet (70%). Abnormal positive glands were identified by 99mTc-MIBI scintigraphy in 27 out of 30 patients (53 glands). The sensitivity and specificity of99mTc-MIBI in detecting cinacalcet response were 90 and 89%, respectively. The mean baseline and posttreatment grades of 99mTc-MIBI uptake were 2.9±1.8 and 1.1±1.2 (P<0.0001) in the responder group and 3.1±2.1 and 3.9±2.2 (P = ns) in the nonresponder group.

Conclusion: 99mTc-MIBI scintigraphy is useful in monitoring the response to calcimimetics in secondary hyperparathyroidism.